Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EKF Diagnostics HoldingsLSE:EKF -0.20%42 Debt-to-Equity is 0.02 as of Dec. 2025, which is at its 10-year median of 0.02. GuruFocus rates LSE:EKF with a GF Score™ of 42/100 and a GF Value™ of £0.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 697 Medical Devices & Instruments companies, EKF Diagnostics Holdings ranks better than 93.54% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for EKF Diagnostics Holdings's Debt-to-Equity or its related term are showing as below:
LSE:EKF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.1
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of EKF Diagnostics Holdings was 0.10. The lowest was 0.01. And the median was 0.02.
LSE:EKF's Debt-to-Equity is ranked better than 93.54% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs LSE:EKF: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
EKF Diagnostics Holdings Debt-to-Equity Related Terms
EKF Diagnostics Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:EKF vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, EKF Diagnostics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EKF Diagnostics Holdings Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EKF Diagnostics Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where EKF Diagnostics Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKF Diagnostics Holdings (LSE:EKF) has a Debt-to-Equity of 0.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on EKF Diagnostics Holdings and its competitors. This is near median its historical median of 0.02. Over the past decade, EKF Diagnostics Holdings' Debt-to-Equity has ranged from 0.01 to 0.10. According to the industry distribution chart, EKF Diagnostics Holdings ranks #45 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 6.5%.
Is EKF Diagnostics Holdings' Debt-to-Equity too high?
EKF Diagnostics Holdings' current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.10. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. EKF Diagnostics Holdings' value of 0.02 is 91.7% below this industry median. Based on the distribution chart, EKF Diagnostics Holdings ranks #45 out of 697 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, EKF Diagnostics Holdings has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EKF Diagnostics Holdings' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EKF Diagnostics Holdings ranks #45 out of 697 companies for Debt-to-Equity. This places EKF Diagnostics Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.24. EKF Diagnostics Holdings' value of 0.02 is 91.7% below this benchmark. Historically, EKF Diagnostics Holdings' own Debt-to-Equity has ranged from 0.01 to 0.10 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.24, EKF Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EKF Diagnostics Holdings's current Debt-to-Equity of 0.02 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on EKF Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EKF Diagnostics Holdings's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EKF Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, EKF Diagnostics Holdings (LSE:EKF) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.28, compared to a current price of £0.25 — trading 9.8% below its estimated fair value. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 91.7% below the Medical Devices & Instruments industry median of 0.24. EKF Diagnostics Holdings' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For EKF Diagnostics Holdings (LSE:EKF), the current Debt-to-Equity is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EKF Diagnostics Holdings (LSE:EKF) Overvalued in 2026?
Based on GuruFocus' analysis, EKF Diagnostics Holdings stock appears to be undervalued.
The current stock price of £0.25 is trading 9.8% below its estimated GF Value™ of £0.28.
GuruFocus considers EKF Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:EKF:
Debt-to-Equity: 0.02 (near median its 10-year median of 0.02)
GF Value™: £0.28 vs. price of £0.25 (9.8% below fair value)
Industry Position: 91.7% below the Medical Devices & Instruments median (#45 of 697)
No single metric tells the full story. See the LSE:EKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.
42GF Score
Get the complete analysis for LSE:EKF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:EKF has been successfully added to your 
